Oak Hill Bio and RACC III Propose Rare-Disease Combination

Company Oak Hill Bio, Research Alliance Corporation III (RACC III) Event Type Financing (Proposed SPAC Business Combination) Modality Antisense oligonucleotide Asset Rugonersen Target UBE3A antisense transcript (paternal-allele unsilencing) Disease Area Angelman syndrome Summary Oak Hill Bio and Research Alliance Corporation III agreed to a business…